Product Center
Ab&B Bio-Tech Co., Ltd. JS Quadrivalent Influenza Virus Subunit Vaccine Marketing Application Has Been Accepted by the National Medical Products Administration!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-21
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed market application for the unadjuvanted quadrivalent influenza virus subunit vaccine for individuals aged 3 and above was accepted by the National Medical Products Administration (NMPA) of China. This is the first market application for a quadrivalent influenza virus subunit vaccine accepted by the NMPA.
Ab&B Bio-Tech Co., Ltd. JS Quadrivalent Influenza Virus Subunit Vaccine Marketing Application Has Been Accepted by the National Medical Products Administration!
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed market application for the unadjuvanted quadrivalent influenza virus subunit vaccine for individuals aged 3 and above was accepted by the National Medical Products Administration (NMPA) of China. This is the first market application for a quadrivalent influenza virus subunit vaccine accepted by the NMPA.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-21 16:16
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. JS's independently developed market application for the unadjuvanted quadrivalent influenza virus subunit vaccine for individuals aged 3 and above was accepted by the National Medical Products Administration (NMPA) of China. This is the first market application for a quadrivalent influenza virus subunit vaccine accepted by the NMPA.

Source: CDE Website
The Ab&B Bio-Tech Co., Ltd. JS quadrivalent influenza virus subunit vaccine is a component vaccine containing a new antigen form, characterized by high purity, low vaccination side effects, and good safety. In 2016, the company applied for clinical trials of the quadrivalent influenza virus subunit vaccine using its own patented technology. In 2017, the company obtained clinical approval for two Class 1 biological new drugs in adult and pediatric dosage forms. From 2018 to 2021, the Phase I/III clinical trial was successfully completed, and all relevant trial results reached clinical endpoints, showing significant positive results in immunogenicity and safety.
The clinical results show that the full-dose unadjuvanted (0.5ml) quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accepted for the company's marketing application, is a safe and effective influenza vaccine that can provide broader and sufficient protection against seasonal influenza viruses. This vaccine is expected to serve as an important member of the influenza prevention strategy and contribute to China's efforts in the global prevention and control of influenza virus outbreaks and infections.
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us